OneThree Biotech – Redesigning Drug Discovery with Biology-Driven AI

Redesigning Drug Discovery with Biology-Driven AI.

At OneThree Biotech we’re combining systems biology with artificial intelligence to uncover new insights and build the next generation of drug discovery.

Battle Tested

Our approach has been validated in cells, animals, and in the clinic.

With over 20 peer review journals, multiple case studies, and success advancing lead candidates through clinical trials; we’re confident in our approach.

We invite you to read more about our technology in publications, cases studies, news and more.

Publications

True Data-Driven Discovery

Each type of data provides a different piece of the puzzle, yet most approaches only use one or two sources.

We’ve built our platform to integrate over 30 types of chemical, biological, and clinical data for each task. This leads to significant increase in accuracy, interpretability, and chance of clinical success.

Our approach

Beyond One Part of the Pipeline

We’re answering questions across the entire development process.

From identifying new targets to optimizing compounds for toxicity or efficacy – our platform evaluates preclinical R&D as a whole. Our holistic view enables us to share data and insights across the drug development pipeline, leading to informed and expansive insights.

Currently we’ve built in over 14 different algorithms into the platform and we’re constantly adding in more.

Our approach

What We Do

Novel Target
Discovery

Candidate and Combination Selection

Mechanism of Action Discovery

AMDE & Toxicity

Therapeutic Positioning

” OneThree’s AI platform helped answer direct mechanistic questions on our top drug candidates, opened up new therapeutic opportunities, helped solve problems that we had been working on for years, and potentially saved several years of additional work. I expect that the approach OneThree Biotech is taking will be integral to the future of drug discovery and development. “

– Josh Allen, PhD, Senior Vice President: Research and Development, Oncoceutics